Physician profile
Shannon D Jackson
NPI 1811323645
$7,689.43
in general payments reported to CMS, 2019-2025
16 companies · $2,524 in 2025
The $2,524 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $693 · 2023: $1,758 · 2024: $2,523 · 2025: $2,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,478 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,478.32 |
| Education | $326.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,460.11 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $1,067.23 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $1,005.29 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $715.61 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $589.72 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $545.22 | 2024-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $446.89 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $326.17 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $192.82 | 2024 | Fanapt |
| Indivior INC. | $131.90 | 2022-2024 | Perseris |
| Boston Scientific Corporation | $70.72 | 2021 | |
| Horizon Therapeutics Plc | $42.19 | 2021 | |
| Amgen INC. | $39.40 | 2021-2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $23.78 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $18.64 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.